Aravive, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2023-11-03: Form 8-K; Period of report 2023-11-02; Description 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; Details 5.03.
- 2023-10-03: Form 8-K; Period of report 2023-10-02; Description 5.07 Submission of Matters to a Vote of Security Holders; Details 5.07.
- 2023-09-19: Form 8-K; Period of report 2023-09-15; Description 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; Details 3.01.
- 2023-08-02: Form 8-K; Period of report 2023-08-02; Description 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 8.01 Other Events; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2023-11-03 | 8-K | 2023-11-02 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 5.03 On November 2, 2023, the board of directors of Aravive, Inc. (the “Company”) amended the Company’s amended and restated bylaws, effective November 2, 2023, in order to amend the quorum requirement of Article III, Section 8, of the amended and restated bylaws, such that the presence in person or by proxy of the holders of thirty-four percent (34%) of the outstanding shares of stock entitled to vote at the meeting shall constitute a quorum for the transaction of business at all meetings of the stockholders. | arav20231103_8k.htm |
| 2023-10-03 | 8-K | 2023-10-02 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On October 2, 2023, Aravive, Inc. (the “Company”) held its 2023 Annual Meeting of Stockholders (the “Annual Meeting”) at which the Company’s stockholders voted on six (6) proposals (the “Proposals”) and cast their votes as described below. | arav20231002_8k.htm |
| 2023-09-19 | 8-K | 2023-09-15 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On September 15, 2023, Aravive, Inc.(the “Company”), received a letter from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the preceding 30 consecutive business days (August 3, 2023 through September 14, 2023), the market value of the Company’s listed securities (“MVLS”) did not maintain a minimum market value of $50,000,000 (the “Minimum MVLS Requirement”) as required by Nasdaq Listing Rule 5450(b)(2)(A). | arav20230918_8k.htm |
| 2023-08-02 | 8-K | 2023-08-02 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 8.01 Other Events | 2.02 Although it has not yet finalized its full financial results for the second quarter ended June 30, 2023, Aravive, Inc. (the “Company”), announced in a press release on August 2, 2023, that it had cash of approximately $18 million at the end of Q2 that is expected to be sufficient to fund operations into early Q4 2023. 7.01 On August 2, 2023, the Company issued a press release announcing the presentation of top-line results from its Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer (“AXLerate”). 8.01 On August 2, 2023, the Company presented top-line results from its Phase 3 AXLerat trial. | arav20230802_8k.htm |
| 2023-06-05 | 8-K | 2023-06-05 | 7.01 Regulation FD Disclosure | 7.01 Aravive, Inc. (the “Company”) will be making several presentations to investors over the next several weeks. | arav20230603_8k.htm |
| 2023-05-25 | 8-K | 2023-05-25 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On May 25, 2022, Aravive, Inc. (the “Company”) issued a press release announcing the presentation of updated results from its ongoing Phase 2 trial of batiraxcept in clear cell renal cell carcinoma (ccRCC) at the 2023 American Society of Clinical Oncology (ASCO) annual meeting, taking place June 2-6, 2023 in Chicago, IL and virtually. 8.01 The Company presented updated results from its ongoing Phase 2 trial of batiraxcept in clear cell renal cell carcinoma (ccRCC) at the 2023 American Society of Clinical Oncology (ASCO) annual meeting, taking place June 2-6, 2023 in Chicago, IL and virtually. | arav20230523_8k.htm |
| 2023-05-16 | 8-K | 2023-05-16 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On May 16, 2023, Aravive, Inc. (the “Company”) issued a press release attached hereto as Exhibit 99.1 announcing that the Company has received guidance from the U.S. Food and Drug Administration (FDA) on a registrational Phase 3 trial design for batiraxcept in clear cell renal cell carcinoma (ccRCC) at an End-of-Phase 2 (EOP2) meeting. 8.01 On May 16, 2023, the Company issued a press release announcing that the Company has received guidance from the U.S. Food and Drug Administration (FDA) on a registrational Phase 3 trial design for batiraxcept in clear cell renal cell carcinoma (ccRCC) at an End-of-Phase 2 (EOP2) meeting. | arav20230515_8k.htm |
| 2023-05-10 | 8-K | 2023-05-10 | 2.02 Results of Operations and Financial Condition | 2.02 On May 10, 2023, Aravive, Inc., a Delaware corporation (the “Registrant”), issued a press release that included financial information for its quarter ended March 31, 2023. | arav20230209_8k.htm |
| 2023-04-11 | 8-K | 2023-04-10 | 3.02 Unregistered Sales of Equity Securities; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 3.02 The disclosure in Item 5.02 of this Current Report on Form 8-K regarding the employee inducement award is incorporated by reference into this Item 3.02. 5.02 Effective as of April 10, 2023, Aravive, Inc. (the “Company”) appointed Maria Carolina Petrini to serve as the Company’s Chief Commercial Officer. 7.01 On April 11, 2023, the Company issued a press release regarding the matters discussed in Item 5.02 above. | arav20230409_8k.htm |
| 2023-03-15 | 8-K | 2023-03-15 | 2.02 Results of Operations and Financial Condition | 2.02 On March 15, 2023, Aravive, Inc., a Delaware corporation (the “Registrant”), issued a press release that included financial information for its fourth quarter and year ended December 31, 2022. | arav20230301_8k.htm |
| 2023-02-28 | 8-K | 2023-02-28 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On February 28, 2023, Aravive, Inc. (the “Company”) issued a press release attached hereto as Exhibit 99.1 announcing that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to batiraxcept for the treatment of pancreatic ductal adenocarcinoma cancer (PDAC). 8.01 On February 28, 2023, the Company issued a press release announcing that the FDA has granted Orphan Drug Designation to batiraxcept for the treatment of pancreatic ductal adenocarcinoma cancer (PDAC). | arav20230228_8k.htm |
| 2023-02-13 | 8-K | 2023-02-13 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On February 13, 2022, Aravive, Inc. (the “Company”) issued a press release announcing the presentation of updated results from its ongoing Phase 1b/2 trial of batiraxcept in clear cell renal cell carcinoma (ccRCC) at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place February 16-18, 2023 in San Francisco and virtually. 8.01 The Company presented updated Phase 1b/2 ccRCC data at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place February 16-18, 2023 in San Francisco and virtually. | arav20230213_8k.htm |
| 2023-02-06 | 8-K | 2023-02-01 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Effective February 1, 2023, Aravive, Inc. (the “Company”) entered into (i) an amendment (the “McIntyre Amendment”), to the Offer Letter that it had entered into with Gail McIntyre, Ph.D., the Company’s Chief Executive Officer, on March 26, 2020, as amended on April 8, 2020 and January 25, 2021 to increase her annual base salary of $560,000; (ii) an amendment (the “Howard Amendment”), to the Offer Letter that it had entered into with Rudy Howard, the Company’s Chief Financial Officer, on June 2, 2022 to increase his annual base salary of $412,775; (iii) an amendment to the Offer Letter (the “Geller Offer Letter”) that it had entered into with Robert Geller, M.D., the Company’s Chief Medical Officer, on June 13, 2022 to increase his annual base salary of $450,000; and (iv) an amendment to the Offer Letter that it had entered into with Leonard Scott Dove, Ph.D. the Company’s Chief Operating Officer, on February 20, 2022 to increase his annual base salary of $405,000. | arav20230206_8k.htm |
| 2023-01-18 | 8-K | 2023-01-13 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 5.07 Submission of Matters to a Vote of Security Holders | 5.03 On January 17, 2023, Aravive, Inc. (the “Company”) filed a Certificate of Amendment (the “Certificate of Amendment”) of the Company’s Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to increase the number of the Company’s authorized shares of common stock, par value $0.0001 per share (the “Common Stock”), from 100,000,000 to 250,000,000. 5.07 On January 13, 2023, the Company held its 2023 Special Meeting of Stockholders (the “Special Meeting”) at which the Company’s stockholders voted on two (2) proposals (the “Proposals”) and cast their votes as described below. | arav20230117_8k.htm |
| 2023-01-04 | 8-K | 2023-01-04 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On January 4, 2023, Aravive, Inc. (the “Company”) issued a press release attached hereto as Exhibit 99.1 announcing that the Company had achieved full enrollment in its registrational Phase 3 trial of batiraxcept plus paclitaxel for platinum-resistant ovarian cancer (“PROC”). 8.01 On January 4, 2023, the Company issued a press release announcing that the Company had achieved full enrollment in its registrational Phase 3 trial of batiraxcept plus paclitaxel for PROC. | arav20221228_8k.htm |
| 2023-01-03 | 8-K | 2023-01-03 | 8.01 Other Events | 8.01 On November 17, 2022, Aravive, Inc. (the “Company”) filed with the U.S. Securities and Exchange Commission (the “SEC”) a preliminary proxy statement on Schedule 14A relating to the special meeting of the Company’s stockholders to be held on January 13, 2023 to, among other things, vote on a proposal to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock, par value $0.0001 per share (the “Common Stock”), from 100,000,000 to 250,000,000 (the “Increase in Number of Authorized Shares of Common Stock Proposal”). | arav20230103_8k.htm |